Literature DB >> 3017016

Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody.

S Yoden, H Kida, M Kuwabara, R Yanagawa, R G Webster.   

Abstract

To study the conformational changes in the hemagglutinin (HA) molecule of A/seal/Mass/1/80 (H7N7) (Seal) influenza virus at low pH, a spin-labeling method was used. This method also permits study of antibody interaction with the HA. A synthetic nitroxide compound was used for spin-labeling of tyrosine residues of the isolated HA molecule. Electron spin resonance (ESR) spectra of the spin-labeled HA at various pH values indicated that a conformational transition occurred under acidic conditions, and around pH 5.8 the HA molecule has maximal flexibility. Since virus-induced hemolysis occurs optimally at pH 5.8-5.9, the HA molecule in the maximally flexible conformation is considered to mediate membrane fusion. The ESR spectra of the antibody-bound HA at various pH values revealed that monoclonal antibodies to different regions on the molecule may inhibit the conformational change by different modes. One antibody inhibited the changes in the HA that resulted in flexibility, while the other did not. These results support the assumption that monoclonal antibodies, which failed to inhibit hemagglutination of the virus yet neutralized viral infectivity, inhibited the fusion step in the viral replication process by interfering with a low pH-induced conformational change in the HA molecule (Kida, H., Webster, R.G. and Yanagawa, R. (1983) Arch. Virol. 76, 91-99).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017016     DOI: 10.1016/0168-1702(86)90004-3

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

Review 1.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

2.  Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.

Authors:  D C Powers; E D Kilbourne; B E Johansson
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

Review 3.  Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Authors:  Manon M J Cox; Ruvim Izikson; Penny Post; Lisa Dunkle
Journal:  Ther Adv Vaccines       Date:  2015-07

4.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.

Authors:  B E Johansson; D J Bucher; E D Kilbourne
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Authors:  David L Gordon; Dimitar Sajkov; Richard J Woodman; Yoshikazu Honda-Okubo; Manon M J Cox; Susanne Heinzel; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-17       Impact factor: 3.641

6.  Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

Authors:  Matthew R Sandbulte; Gretchen S Jimenez; Adrianus C M Boon; Larry R Smith; John J Treanor; Richard J Webby
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

7.  Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine.

Authors:  Yoshikazu Honda-Okubo; Harinda Rajapaksha; Dimitar Sajkov; David Gordon; Manon M J Cox; Nikolai Petrovsky
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 8.  Strategies for fighting pandemic virus infections: Integration of virology and drug delivery.

Authors:  Takashi Nakamura; Norikazu Isoda; Yoshihiro Sakoda; Hideyoshi Harashima
Journal:  J Control Release       Date:  2022-02-03       Impact factor: 11.467

9.  Mapping antibody epitopes of the avian H5N1 influenza virus.

Authors:  Hui-Ling Yen; J S Malik Peiris
Journal:  PLoS Med       Date:  2009-04-21       Impact factor: 11.069

Review 10.  FluBlok, a recombinant hemagglutinin influenza vaccine.

Authors:  Manon M J Cox; Peter A Patriarca; John Treanor
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.